<DOC>
	<DOCNO>NCT00834002</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's white blood cell ( dendritic cell ) specific leukemia antigen ( Wilms tumor antigen-1 ) may induce effective immune response kill residual leukemic cell and/or prevent leukemia relapse . PURPOSE : This phase I/II trial study feasibility , safety efficacy intradermal mRNA-transfected dendritic cell vaccination therapy patient acute myeloid leukemia .</brief_summary>
	<brief_title>Dendritic Cell Vaccination Patients With Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>Autologous dendritic cell ( DC ) vaccination promise strategy adjuvant cancer therapy set minimal residual disease ( MRD ) . We perform phase I/II trial patient acute myeloid leukemia ( AML ) patient receive intradermal injection autologous DC load mRNA cod Wilms ' tumor protein ( WT1 ) . WT1 highly overexpressed leukemia level WT1 RNA peripheral blood useful biomarker molecular diagnosis en follow-up MRD setting . We want prospectively monitor WT1 RNA expression peripheral blood vaccinate non-vaccinated AML patient order evaluate predictive value biomarker relapse assess clinical efficacy DC vaccination acute myeloid leukemia patient . We believe , basis already available evidence , use WT1 target immunotherapy well biomarker hold promise assess efficacy new experimental therapeutic intervention DC vaccination .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Tumor type : Acute Myeloid Leukemia ( AML ) accord WHO criteria ( ea least 20 % blast marrow ) . All FAB subtypes except M3 . Patients Myelodysplastic Syndrome , category Refractory Anemia Excess Blasts ( RAEB ) : RAEB I ( WHO : medullary blast count ≤ 10 % peripheral blast count ≤ 5 % ) RAEB II ( WHO : medullary blast count &gt; 10 % and/or &gt; 5 % peripheral blast ) include study absence nonexperimental treatment modality . 2 . Extent disease : remission ( partial complete ) smoulder course . Complete remission ( CR ) define blast peripheral blood 5 % blast bone marrow . This definition relate hematological remission specify . Partial remission ( PR ) define decrease least 50 % percentage blast 5 25 % bone marrow aspirate . Smouldering course define relatively low marrow blast count slowly progressive disease . 3 . Overexpression WT1 RNA ( &gt; 50 copy WT1 per 1000 copy ABL bone marrow &gt; 2 copy/1000 copy ABL peripheral blood ) assess quantitative RTPCR time presentation . 4 . Prior treatment : Patients must receive least one prior antileukemic chemotherapeutic regimen must 1 month past last treatment and/or 6 month past allogeneic/autologous stem cell transplantation . 5 . Age : ≥ 18 year 6 . High risk relapse ( and/or ) Age &gt; 60 year ( &lt; 60 , sibling allotransplant donor available ) Poor risk cytogenetic molecular marker presentation Hyperleukocytosis presentation Second complete remission relapse 7 . Performance status : WHO PS grade 01 ( Appendix B ) 8 . Objectively assessable parameter life expectancy : 3 month 9 . Prior concomitant associate disease allow exception underlie autoimmune disease positive serology HIV/HBV/HCV 10 . No concomitant use immunosuppressive drug 11 . Adequate renal liver function , i.e . creatinin bilirubin = 1.2 time upper limit normal 12 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial 13 . Women childbearing potential use adequate contraception prior study entry duration study participation 1 . Subjects concurrent additional malignancy ( exception Nonmelanoma skin cancer carcinoma situ cervix ) 2 . Subjects pregnant 3 . Subjects sensitivity drug provide local anesthesia 4 . Age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>AML remission</keyword>
</DOC>